Financial Ratios Alibaba Health Information Technology Limited
Equities
241
BMG0171K1018
Drug Retailers
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.170 HKD | 0.00% |
|
+1.15% | +22.18% |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 0.18 | -3.71 | -0.16 | 1.96 | 4.44 | |||||
Return on Total Capital | 0.23 | -4.8 | -0.22 | 2.66 | 5.87 | |||||
Return On Equity % | 3.52 | -1.88 | 3.66 | 5.95 | 9.29 | |||||
Return on Common Equity | 3.56 | -1.87 | 3.64 | 5.95 | 9.28 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 23.22 | 19.96 | 21.3 | 21.81 | 24.29 | |||||
SG&A Margin | 20.2 | 21.73 | 18.89 | 16.83 | 17.1 | |||||
EBITDA Margin % | 0.33 | -5.22 | -0.09 | 2.44 | 4.86 | |||||
EBITA Margin % | 0.25 | -5.27 | -0.13 | 2.41 | 4.81 | |||||
EBIT Margin % | 0.23 | -5.33 | -0.19 | 2.35 | 4.75 | |||||
Income From Continuing Operations Margin % | 2.21 | -1.29 | 2 | 3.27 | 4.68 | |||||
Net Income Margin % | 2.25 | -1.29 | 1.99 | 3.27 | 4.68 | |||||
Net Avail. For Common Margin % | 2.25 | -1.29 | 1.99 | 3.27 | 4.68 | |||||
Normalized Net Income Margin | 1.1 | -2.4 | 1.06 | 2.85 | 4 | |||||
Levered Free Cash Flow Margin | 4.48 | 3.41 | -0.07 | 1.18 | 2.27 | |||||
Unlevered Free Cash Flow Margin | 4.49 | 3.43 | -0.06 | 1.19 | 2.27 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.21 | 1.11 | 1.34 | 1.34 | 1.5 | |||||
Fixed Assets Turnover | 229.53 | 189.31 | 229.08 | 313.87 | 352.95 | |||||
Receivables Turnover (Average Receivables) | 48.64 | 49.61 | 48.89 | 39.63 | 33.3 | |||||
Inventory Turnover (Average Inventory) | 8.87 | 10.91 | 11.53 | 12.07 | 16.46 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.18 | 2.81 | 2.74 | 2.69 | 2.59 | |||||
Quick Ratio | 3.65 | 2.41 | 2.24 | 2.28 | 2.15 | |||||
Operating Cash Flow to Current Liabilities | 0.3 | 0.09 | 0.05 | 0.21 | 0.29 | |||||
Days Sales Outstanding (Average Receivables) | 7.5 | 7.36 | 7.47 | 9.24 | 10.96 | |||||
Days Outstanding Inventory (Average Inventory) | 41.14 | 33.45 | 31.65 | 30.33 | 22.18 | |||||
Average Days Payable Outstanding | 66.25 | 67.04 | 61.15 | 63.28 | 48.83 | |||||
Cash Conversion Cycle (Average Days) | -17.61 | -26.23 | -22.04 | -23.72 | -15.7 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.26 | 0.96 | 0.51 | 0.57 | 0.22 | |||||
Total Debt / Total Capital | 0.26 | 0.95 | 0.51 | 0.56 | 0.22 | |||||
LT Debt/Equity | 0.12 | 0.6 | 0.27 | 0.33 | 0.15 | |||||
Long-Term Debt / Total Capital | 0.12 | 0.6 | 0.26 | 0.33 | 0.15 | |||||
Total Liabilities / Total Assets | 19.49 | 26.71 | 26.99 | 26.33 | 22.97 | |||||
EBIT / Interest Expense | 14.8 | -287.24 | -8.83 | 106.36 | 557.15 | |||||
EBITDA / Interest Expense | 30.98 | -271.36 | 2.09 | 115.35 | 579.23 | |||||
(EBITDA - Capex) / Interest Expense | 24.01 | -275.27 | 1.13 | 111.54 | 571.99 | |||||
Total Debt / EBITDA | 0.5 | -0.13 | 6.37 | 0.12 | 0.02 | |||||
Net Debt / EBITDA | -152.86 | 10.06 | -887.38 | -13.76 | -5.34 | |||||
Total Debt / (EBITDA - Capex) | 0.64 | -0.13 | 11.78 | 0.12 | 0.02 | |||||
Net Debt / (EBITDA - Capex) | -197.26 | 9.92 | -1.64K | -14.23 | -5.4 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 61.71 | 32.6 | 30.06 | 0.98 | 13.22 | |||||
Gross Profit, 1 Yr. Growth % | 61.85 | 13.57 | 38.79 | 3.4 | 26.07 | |||||
EBITDA, 1 Yr. Growth % | -196.02 | -2.16K | -97.73 | -2.79K | 125.54 | |||||
EBITA, 1 Yr. Growth % | -158.03 | -2.85K | -96.87 | -2.02K | 125.6 | |||||
EBIT, 1 Yr. Growth % | -153.77 | -3.02K | -95.31 | -1.33K | 128.97 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -2.28K | -177.61 | -300.9 | 64.61 | 62.15 | |||||
Net Income, 1 Yr. Growth % | -5.39K | -176.18 | -300.86 | 64.93 | 62.14 | |||||
Normalized Net Income, 1 Yr. Growth % | -1.63K | -387.43 | -157.55 | 170.33 | 59.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -4.47K | -175.19 | -300 | 58.33 | 41.63 | |||||
Accounts Receivable, 1 Yr. Growth % | -3.37 | 64.53 | 12.17 | 35.65 | 34.06 | |||||
Inventory, 1 Yr. Growth % | 20.65 | 5.55 | 35.62 | -33.42 | 1.11 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -36.95 | 215.76 | -58.48 | 51.23 | -32.75 | |||||
Total Assets, 1 Yr. Growth % | 125.4 | 8.25 | 8.05 | -5.02 | 7.48 | |||||
Tangible Book Value, 1 Yr. Growth % | 173.4 | -9.01 | 8.43 | -4.36 | 13.28 | |||||
Common Equity, 1 Yr. Growth % | 171.43 | -1.42 | 7.63 | -4.15 | 12.16 | |||||
Cash From Operations, 1 Yr. Growth % | 72.96 | -57.96 | -39.75 | 322.32 | 29.19 | |||||
Capital Expenditures, 1 Yr. Growth % | 125.68 | -12.57 | -62.41 | 305.81 | -17.04 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 23.13 | 0.92 | -102.79 | -1.73K | 117.48 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 20.48 | 1.04 | -102.27 | -2.12K | 115.47 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 74.51 | 46.43 | 31.32 | 14.6 | 6.93 | |||||
Gross Profit, 2 Yr. CAGR % | 64.58 | 35.85 | 25.54 | 19.8 | 14.17 | |||||
EBITDA, 2 Yr. CAGR % | -26.47 | 350.02 | -31.48 | -21.78 | 679.1 | |||||
EBITA, 2 Yr. CAGR % | -37.57 | 305.42 | -7.22 | -22.55 | 557.72 | |||||
EBIT, 2 Yr. CAGR % | -39.23 | 303.15 | 17.24 | -23.98 | 431.26 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 93.24 | 311.62 | 24.86 | 82.23 | 63.37 | |||||
Net Income, 2 Yr. CAGR % | 106.25 | 534.99 | 23.7 | 82.4 | 63.53 | |||||
Normalized Net Income, 2 Yr. CAGR % | 90.58 | 563.59 | 28.84 | 24.73 | 107.41 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 88.01 | 472.99 | 22.63 | 78.41 | 49.75 | |||||
Accounts Receivable, 2 Yr. CAGR % | -7.36 | 26.09 | 35.85 | 23.35 | 34.85 | |||||
Inventory, 2 Yr. CAGR % | 57 | 12.85 | 19.65 | -4.98 | -17.95 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 142.58 | 41.1 | 14.5 | -20.76 | 0.85 | |||||
Total Assets, 2 Yr. CAGR % | 72.21 | 56.2 | 8.15 | 1.3 | 1.03 | |||||
Tangible Book Value, 2 Yr. CAGR % | 126.87 | 57.73 | -0.67 | 1.83 | 4.09 | |||||
Common Equity, 2 Yr. CAGR % | 126.23 | 63.57 | 3 | 1.57 | 3.68 | |||||
Cash From Operations, 2 Yr. CAGR % | 59.58 | -14.73 | -49.67 | 59.52 | 133.58 | |||||
Capital Expenditures, 2 Yr. CAGR % | 67.29 | 40.46 | -42.67 | 23.51 | 83.48 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 28.94 | 11.53 | -83.23 | -32.56 | 495.09 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 26.47 | 10.39 | -84.89 | -32.28 | 560.45 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 85.21 | 59.24 | 40.76 | 20.31 | 14.14 | |||||
Gross Profit, 3 Yr. CAGR % | 76.93 | 45.63 | 36.82 | 17.68 | 21.85 | |||||
EBITDA, 3 Yr. CAGR % | -27.86 | 125.08 | -22.72 | 132.91 | 11.34 | |||||
EBITA, 3 Yr. CAGR % | -35.13 | 122.67 | -19.82 | 154.62 | 10.61 | |||||
EBIT, 3 Yr. CAGR % | -36.29 | 123.49 | -8.59 | 156.84 | 9.79 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 46.48 | 42.57 | 224.08 | 37.1 | 75.28 | |||||
Net Income, 3 Yr. CAGR % | 48.26 | 47.98 | 332.66 | 36.34 | 75.38 | |||||
Normalized Net Income, 3 Yr. CAGR % | 47.2 | 118.88 | 194.07 | 64.94 | 35.28 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 31.04 | 38.52 | 303.44 | 33.76 | 65.19 | |||||
Accounts Receivable, 3 Yr. CAGR % | 50.84 | 12.19 | 21.27 | 35.78 | 26.82 | |||||
Inventory, 3 Yr. CAGR % | 49.19 | 37.54 | 19.98 | -1.59 | -2.99 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 102.75 | 164.86 | -6.15 | 25.63 | -24.98 | |||||
Total Assets, 3 Yr. CAGR % | 78.65 | 47.51 | 38.14 | 3.57 | 3.32 | |||||
Tangible Book Value, 3 Yr. CAGR % | 77.18 | 67.31 | 39.2 | -1.92 | 5.51 | |||||
Common Equity, 3 Yr. CAGR % | 76.97 | 71.51 | 42.27 | 0.56 | 4.98 | |||||
Cash From Operations, 3 Yr. CAGR % | 143.09 | 2.3 | -24.05 | 2.27 | 48.69 | |||||
Capital Expenditures, 3 Yr. CAGR % | 43.9 | 34.75 | -9.48 | 10.07 | 8.16 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 67.19 | 18.87 | -67.4 | -22.92 | -0.37 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 69.75 | 17.39 | -69.8 | -22.68 | -0.4 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 207.34 | 112.48 | 61.41 | 39.61 | 26.1 | |||||
Gross Profit, 5 Yr. CAGR % | 148.54 | 85.46 | 54.37 | 34.69 | 27.27 | |||||
EBITDA, 5 Yr. CAGR % | -24.87 | 40.27 | -29 | 47.55 | 94.75 | |||||
EBITA, 5 Yr. CAGR % | -29.27 | 39.88 | -24.67 | 46.03 | 86.06 | |||||
EBIT, 5 Yr. CAGR % | -30.03 | 40.19 | -18.15 | 45.26 | 84.81 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 11.49 | 4.97 | 37.42 | 57.28 | 146.62 | |||||
Net Income, 5 Yr. CAGR % | 12.71 | 5.04 | 37.9 | 60.89 | 193.42 | |||||
Normalized Net Income, 5 Yr. CAGR % | 8.4 | 30.35 | 39.68 | 74.91 | 155.74 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 2.25 | -4.95 | 27.61 | 53.27 | 171.68 | |||||
Accounts Receivable, 5 Yr. CAGR % | 394.56 | 68.05 | 44.66 | 16.53 | 26.53 | |||||
Inventory, 5 Yr. CAGR % | - | 59.22 | 36.59 | 18.63 | 3.06 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 51.53 | 100.74 | 61.32 | 63.45 | -3.41 | |||||
Total Assets, 5 Yr. CAGR % | 67.43 | 62.79 | 46.16 | 26.93 | 21.89 | |||||
Tangible Book Value, 5 Yr. CAGR % | 63.44 | 62.08 | 40.56 | 37.17 | 23.92 | |||||
Common Equity, 5 Yr. CAGR % | 63.57 | 64.29 | 42.52 | 39.08 | 25.36 | |||||
Cash From Operations, 5 Yr. CAGR % | 53.83 | 13.4 | 29.48 | 22.19 | 19.04 | |||||
Capital Expenditures, 5 Yr. CAGR % | 14.35 | 47.48 | -0.42 | 30.13 | 20.08 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 78.53 | 59.47 | -33.35 | -5.29 | 4.18 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 78.61 | 61.67 | -35.48 | -5.84 | 3.74 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















